People In The News: New Top Leadership At IoM, Avillion, Sucampo; Former FDA Orphan Drug Head Update
Executive Summary
The Institute of Medicine names Victor Dzau president; Avillion names Jeynes-Ellis CEO, while Sucampo introduces Greenleaf as its new CEO; Former FDA Office of Orphan Drug Product Development Director Timothy Cote joins Xenetic Biosciences board; more announcements in this month’s column.
You may also be interested in...
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.
Observational Study Quality Checklist Gets Mixed Reviews In Validation Study
The validation study finds challenges in correlating expert opinion on what is a good observational study that can be used for decision making and what the GRACE Initiative checklist predicts is a good study. Validation study author Robert Dubois believes the checklist can be predictive of a good study when the context of how an observational study’s findings are to be used is clear.